Evidence map›Paper›PMID 38514270›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2024

[New progress in the first-line treatment of advanced hepatocellular carcinoma].

C H Zhang, D Y Yao, S Q Liu, L L Yang, Z J Jin

Open access · greenAbstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. [Analysis of epidemiological trends from 1990 to 2021 of liver cancer in China].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

C H ZhangDepartment of Hepatopancreatobiliary Medicine, the Second Hospital, Jilin University, Changchun 130041, China.
D Y YaoDepartment of Oral, Plastic and Aesthetic Surgery, Hospital of Stomatology, Jilin University, Changchun 130021, China.
S Q LiuDepartment of Hepatopancreatobiliary Medicine, the Second Hospital, Jilin University, Changchun 130041, China.
L L YangDepartment of Hepatopancreatobiliary Medicine, the Second Hospital, Jilin University, Changchun 130041, China.
Z J JinDepartment of Hepatopancreatobiliary Medicine, the Second Hospital, Jilin University, Changchun 130041, China.
Second Affiliated Hospital of Jilin University · CNJilin University · CN

Funding

Natural Science Foundation of Jilin Province YDZJ202201ZYTS288, 20200201482JC
6 · The paper itself

Abstract

Hepatocellular carcinoma is a kind of cancer with a strong invasion, a high incidence rate and mortality, and a poor prognosis. At the time of diagnosis, most patients are already in the advanced stages of a tumor and have lost the chance for radical surgical treatment. Advanced hepatocellular carcinoma treatment has a gradual transition from systemic chemotherapy to targeted therapy, immunotherapy, and combination therapy, especially immune checkpoint inhibitor-based immunotherapy combination therapy, such as combination with bevacizumab monoclonal antibodies and other drugs, or combination with TACE, HAIC, radiotherapy, ablation, and other treatment methods. Combination therapy has significant synergistic effects and thus has already become a future treatment trend for hepatocellular carcinoma. An immunotherapy-based combination therapy plan will run through the whole process of systemic therapy, which is expected to bring better survival benefits to patients with hepatocellular carcinoma. This article reviews the latest research progress in aspects of the first-line treatment of advanced hepatocellular carcinoma.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsCombined Modality TherapyHumansImmunotherapyCombination therapyHepatocellular carcinomaImmunotherapyTargeted therapy

Identifiers

PMID38514270
PMCPMC12850701
OpenAlexW4394739139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.